Medicinal Products

773. Deputy Ken O'Flynn asked the Minister for Health whether dispensing trends for salbutamol nebules are monitored as part of winter preparedness or respiratory surveillance planning. [36448/26]

774. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains regional prescribing trend analysis for nebulised bronchodilator medications; and if so, to provide the latest available data. [36449/26]

775. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken into the drivers of variation in average reimbursement cost per salbutamol nebule item under the General Medical Services scheme since 2024. [36450/26]

777. Deputy Ken O'Flynn asked the Minister for Health whether the Department has assessed the extent to which high-frequency salbutamol dispensing may indicate gaps in preventative asthma or COPD management in primary care. [36452/26]

778. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has identified any supply-chain, pricing or reimbursement pressures affecting nebulised respiratory medications since 2024. [36453/26]

781. Deputy John Lahart asked the Minister for Health the specific steps being taken to ensure the HSE considers the "time-critical" nature of Friederichs Ataxia during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to …

231. Deputy Pearse Doherty asked the Minister for Health when a decision will be made on the availability and funding of givinostat for Duchenne muscular dystrophy; and if she will make a statement on the matter. [35421/26]

1019. Deputy Donna McGettigan asked the Minister for Health to ensure a person (details supplied) will receive a discretionary hardship payment as an interim support, pending the outcome of the acarizax reimbursement application due to significant financial hardship and the medical necessity of the treatment; and if she will make a statement on the matter. [33989/26]

1191. Deputy Mary Lou McDonald asked the Minister for Health the position in relation to the approval of the drug ryeqo which is used in other jurisdictions in the treatment of endometriosis; and if she will make a statement on the matter. [35037/26]

1215. Deputy Pádraig O'Sullivan asked the Minister for Health if she will outline what steps her Department is taking to address the fact that brexpiprazole and lurasidone, two antipsychotic medicines now recommended as first-line treatment options for females with first-episode psychosis in the first international clinical guideline of its kind published in March 2026, are currently licensed in I…

1217. Deputy Pádraig Rice asked the Minister for Health the reason that a supplement (details supplied) has not been made available under the drugs payment scheme; the actions necessary for this supplement to be made eligible for reimbursement under the scheme; and if she will make a statement on the matter. [35192/26]

1240. Deputy Colm Burke asked the Minister for Health whether she is concerned about the promotion and sale of obesity medicines to under-18s for cosmetic weight-loss purposes by black-market actors; and if she will make a statement on the matter. [35309/26]

476. Deputy Gillian Toole asked the Minister for Health if information (details supplied) in relation to a series of matters regarding the policy, clinical and financial rationale for restricting access to long-acting injectable buprenorphine will be provided; and if she will make a statement on the matter. [33481/26]

493. Deputy John Connolly asked the Minister for Health further to Parliamentary Question No. 1964 of 18 March 2026, relating to omaveloxolone skyclarys®, whether any interim arrangements are available or under consideration whereby, in circumstances where a family is willing to travel abroad, a patient could be facilitated in accessing this treatment while the drug remains under assessment by the…

540. Deputy Ken O'Flynn asked the Minister for Health to clarify the current operational status of any early access or compassionate access schemes for rare disease medicines; and to confirm whether any such schemes are currently available to patients in Ireland. [33756/26]

826. Deputy Colm Burke asked the Minister for Children, Disability and Equality whether she is concerned about the promotion and sale of obesity medicines to under-18s for cosmetic weight-loss purposes by black-market actors. [33442/26]

828. Deputy Colm Burke asked the Minister for Health the plans to tackle the promotion and sale of counterfeit obesity medicines online and offline which are in breach of the law, endanger public health and can contribute to organised crime. [32947/26]

829. Deputy Pádraig O'Sullivan asked the Minister for Health the steps her Department is taking to ensure continuity of medication management supports for adults and children with disabilities and cognitive impairment, particularly in respect of the safe use of monitored dosage systems where these are clinically indicated; and if she will make a statement on the matter. [33043/26]

830. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has carried out, or commissioned, any assessment of the impact on persons with disabilities of the requirement to privately fund pharmacist-prepared blister packs and monitored dosage systems where such supports are recommended on safety grounds; and if she will make a statement on the matter. [33044/26]

832. Deputy Rose Conway-Walsh asked the Minister for Health whether the drug sotatercept, approved for the treatment of pulmonary hypertension in other jurisdictions, will be made available to patients in Ireland; and if she will make a statement on the matter. [31813/26]

834. Deputy Louis O'Hara asked the Minister for Health if people living with type 2 diabetes could be made eligible for free dexcom continuous glucose monitoring (CGM) devices under the long-term illness scheme; and if she will make a statement on the matter. [31851/26]

838. Deputy Albert Dolan asked the Minister for Health whether she is satisfied that current reimbursement timelines for orphan medicines align with the commitments on timely and equitable access set out in the National Rare Disease Strategy 2025–2030; the measures that are being taken to address delays in cases where EMA-approved treatments, including those for Friedreich’s ataxia, remain unavail…

841. Deputy Ciarán Ahern asked the Minister for Health if consideration is being given to funding the Alzheimer’s drug lecanemab; and if she will make a statement on the matter. [31918/26]

859. Deputy Peter 'Chap' Cleere asked the Minister for Health if she will expedite and accept the appeal of a person (details supplied); and if she will make a statement on the matter. [31983/26]

871. Deputy Barry Ward asked the Minister for Health if her attention has been drawn to delays in the sign off of fertility treatment by the Health Products Regulatory Authority (details supplied); the actions she will take to address this matter; and if she will make a statement on the matter. [32100/26]